RECRUITING

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial compares the use of tobacco flavored electronic cigarettes (ECs) vs. non-tobacco flavored ECs vs. nicotine replacement therapy (patches and lozenges) on smoking behavior in current cigarette smokers. ECs may reduce cigarette craving and withdrawal symptoms, increase motivation and confidence to stop cigarette smoking, and decrease cigarette smoking and dependence. By comparing participants' preferred flavor ECs (PEC) to tobacco flavor ECs (TEC) to NRT, researchers hope to determine the effect of EC flavors on appeal and use and learn how ECs affect smoking behaviors and health.

Official Title

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-Cigarettes on Smoking Behavior

Quick Facts

Study Start:2024-04-10
Study Completion:2028-04-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06260683

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \>= 21 years old
  2. * Smoke \>= 5 cigarettes per day for the past year
  3. * Willing to use either an EC or NRT
  4. * Read and speak English
  5. * Have a smartphone
  1. * Report currently using smoking cessation medications, NRT, or actively seeking treatment for smoking cessation
  2. * Current use of an EC \> 4 days a month
  3. * Diagnosed medical conditions of lung disease, asthma, cystic fibrosis, heart disease or chronic obstructive pulmonary disease (COPD)
  4. * Unmanaged (unmedicated and/or without counseling) diagnosis of schizophrenia
  5. * History of cardiac event or distress within the past 3 months
  6. * Currently pregnant, planning to become pregnant within 6 months, or breastfeeding
  7. * High blood pressure not controlled by medications
  8. * Serious angina pectoris or chest pain
  9. * Stroke within the past three months
  10. * Known allergy to propylene glycol or vegetable glycerin
  11. * Serious underlying arrhythmias, irregular heartbeat or abnormal heart rhythm
  12. * Live in same household as another study participant

Contacts and Locations

Study Contact

The Ohio State Comprehensive Cancer Center
CONTACT
800-293-5066
OSUCCCClinicaltrials@osumc.edu

Principal Investigator

Theodore L Wagener, PhD
PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center

Study Locations (Sites)

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Ohio State University Comprehensive Cancer Center

  • Theodore L Wagener, PhD, PRINCIPAL_INVESTIGATOR, Ohio State University Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-10
Study Completion Date2028-04-12

Study Record Updates

Study Start Date2024-04-10
Study Completion Date2028-04-12

Terms related to this study

Additional Relevant MeSH Terms

  • Cigarette Smoking-Related Carcinoma